Medscape1d
Pembrolizumab Shows Promise in Two CTCL Subtypes
Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...
Soligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant ...
Innate Pharma: Moving Into The Padcev Space
Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...
Proactive Investors9d
Prescient Therapeutics opens first clinical site for Phase 2a PTX-100 trial in cutaneous T-cell lymphoma
Clinical-stage oncology company Prescient Therapeutics Ltd has opened the first clinical site for its Phase 2a study of ...
BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...
Memorial Sloan Kettering Cancer Center2d
Overcoming Challenges with CAR T Cell Therapy for Patients with Non-Hodgkin Lymphoma
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study For Early-Stage Cutaneous T-Cell Lymphoma Treatment
Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...